On April 28, 2025, Biohaven Ltd. entered into a Note Purchase Agreement which enables it to receive up to $600 million in funding through the sale of senior secured notes, with payments linked to their drug, troriluzole, pending FDA approval. This agreement includes revenue payments based on net sales and milestone payments contingent on regulatory approvals.